Diagnostic standardization of leukemia fusion gene detection system using multiplex reverse transcriptase-polymerase chain reaction in Korea by 理쒖쥌�씫
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
http://dx.doi.org/10.3346/jkms.2011.26.10.1399  •  J Korean Med Sci 2011; 26: 1399-1400
CORRESPONDENCE
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We read the interesting article “Spectra of Chromosomal Aber-
rations in 325 Leukemia Patients and Implications for the De-
velopment of New Molecular Detection Systems” in a recent is-
sue of the Journal of Korean Medical Science by Choi et al. (1). 
We would like to add some comments on these data for suggest-
ing a diagnostic standardization of detection of leukemia-asso-
ciated gene rearrangements in Korea.
 Choi et al. (1) reported that they were able to detect leukemic 
fusion genes among 42% of the entire leukemia patient group, a 
relatively high ratio, by implementing multiplex reverse tran-
scriptase-polymerase chain reaction (RT-PCR) analysis to 325 
leukemia patients over 4 yr. The multiplex RT-PCR kits (Hema-
Vision, DNA technology, Aarhus, Denmark) that was used in the 
study by Choi et al. (1) are useful diagnostic tools that can simul-
taneously detect 28 different fusion genes and 80 or more break-
points or splicing variants, enabling concurrent screening and 
confirmation of various leukemia-related gene rearrangements 
through “Master PCR” (day 1#) and “Split-out PCR” (day 2#). 
Based on the experience accumulated by the authors using the 
same multiplex RT-PCR kits at our institution for recent years, we 
would like to provide a more detailed comment on the merits 
and shortcomings of this test kit.
 First and foremost, the most important merit of HemaVision 
kit is that the screening tests by its “Master PCR” can detect un-
expected rare chromosomal translocations and/or cryptic gene 
rearrangements among new patients with various subtypes of 
leukemia. For example, we were able to identify a very rare NPM1-
MLF1 rearrangement from an acute myeloid leukemia with my-
elodysplasia-related changes (AML-MRC) patient who accom-
panied a complex karyotype by utilizing the multiplex RT-PCR 
testing method (2). Moreover, as the test allows for a clear detec-
tion of various alternative splicing and splice variants on gene 
rearrangements such as BCR-ABL1, PML-RARA, and CBFB-
MYH11, we were even able to identify a new type of variant fu-
sion gene that was not reported on rare occasions (3, 4). Also, in 
case of detection of a rare fusion gene, a “Split-out PCR” of He-
maVision kit enables a semiquantitative monitoring and follow 
up on the minimal residual disease (MRD). From a quality con-
trol perspective, HemaVision is better off than the homebrew 
RT-PCR that has been used in Korean medical institutes in terms 
of maintaining quality control of the results as one can simulta-
neously check internal control bands at 911bp size during the 
test, and also because the consistency and reliability of the test 
result is high. However, it is impossible to detect all types of gene 
rearrangements related to leukemia by HemaVision kits (notice 
that one can only detect 28 types of fusion genes), and there are 
some practical limitations as to the high cost of the kit itself as 
well. For instance, HemaVision cannot detect all types of MLL 
partner genes but only about 10 types, while there are about 70 
types of MLL partner genes including the CASP8AP2 gene that 
was recently identified by the authors with respect to MLL rear-
rangements (1, 5). In the future, however, we hope that addition-
al types of MLL gene rearrangements could be included in such 
multiplex RT-PCR kits, based on the MLL rearrangement status 
for Korean acute leukemia patients and on practical data such 
as domestic incidence of MLL partner gene by type, studies that 
are being conducted by the authors as part of the AML-MDS 
working party project.
 There is no doubt that the research results by Choi et al. is the 
most representative data related to the detection of leukemia-
specific gene rearrangements by multiplex RT-PCR at a single 
medical center in Korea, but the recommended 3 types of cyto-
genetic abnormalities in their paper that are to be included in 
the new multiplex RT-PCR system does not seem to be appro-
priate. Firstly, t(8;14)(q24;q32) seems to be a cytogenetic abnor-
mality which is better suited for the FISH assay rather than the 
RT-PCR method since chromosomal translocation occurs by a 
juxtaposition of the C-MYC (8q24) gene towards the IGH (14q32) 
gene, and there is no hybrid gene. Secondly, although t(3;3)
(q21;q26) is a recurrent cytogenetic abnormality for AML that 
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was newly introduced in the 2008 WHO classification (6), its fre-
quency is known to be relatively low, and it would be more suit-
able to use EVI1 FISH probe in order to simultaneously detect 
variants of t(3;3) such as inv(3)(q21q26) and ins(3;3)(q26;q21q26), 
as well as t(3;21) that is related to RUNX1-MDS1-EVI1 rearrange-
ment. And the lastly mentioned i(17)(q10) cannot be detected 
by RT-PCR since it is not a gene rearrangement but a chromo-
somal abnormality that is related to structural aberration. Addi-
tional comments by Choi et al. would be helpful to clarify on 
these issues.
 In conclusion, detecting gene rearrangements for leukemia 
patients using multiplex RT-PCR kits such as HemaVision seems 
to be a highly useful molecular diagnostic method for Korean 
medical institutions in these days. While there are some practi-
cal limits as mentioned above, a widespread implementation of 
this method throughout the majority of medical institutions in 
Korea will significantly contribute to the standardization of leu-
kemia diagnosis and guarantee high quality test results and ef-
ficient quality control. For the issue of what additional gene re-
arrangements in leukemia patients should be included in the 
multiplex RT-PCR test panel, a continued research and addition-
al discussion would be necessary rather than adhering to the 
current provisional conclusions. 
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